The Phase 2 clinical trial was conducted in Japan, South Korea, and Taiwan in patients with previously untreated, HER2-negative unresectable advanced or recurrent gastric cancer (including ...
Find the latest Otsuka Holdings Co., Ltd. (4578.T) stock quote, history, news and other vital information to help you with your stock trading and investing.
Ono's BMS-partnered EP4 antagonist improves progression-free survival in phase 2 gastric cancer test
Ono Pharmaceutical’s EP4 antagonist hit the primary progression-free survival endpoint in a phase 2 trial in patients with gastric cancer. The biopharma evaluated the Bristol Myers Squibb-partnered ...
ONO-4578, an EP4 antagonist, in combination with Opdivo and chemotherapy demonstrated a significant prolongation of progression-free survival compared with placebo in combination with Opdivo and ...
What Is Otsuka Holdings Ltd (4578) Price Target According to Analysts? The average 12-month price target for Otsuka Holdings Ltd is 11,650.0 JPY, with a high estimate of 15100 JPY and a low estimate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results